Anand Rathi has issued a buy rating on Sharda Cropchem with a target price of ₹1,330, revised upward from the previous target of ₹1,250. According to the broker's research report dated January 30, 2026, the recommendation is based on the company's strong Q3FY26 performance and positive outlook for future growth. The stock is currently valued at 17x FY28e EPS.
Sharda Cropchem demonstrated robust performance in Q3FY26, driven by healthy 14% year-on-year volume growth. As reported by Anand Rathi, the growth was supported by positive product-mix, favorable forex conditions, and market-share gains in key regions. The company benefited from better demand especially in Europe and Latin America, along with near complete de-stocking across major regions.
The broker expects Sharda Cropchem's revenue/EBITDA/PAT to clock 15%/27%/34% CAGR over FY25-28e. According to the research report, management remains confident about sustaining growth momentum in Q4FY26e and FY27e, led by improved demand and pricing scenario. The company is expected to benefit from price hikes in the near term as volumes rise with expanded reach and market penetration.
The management believes prices have bottomed out and is confident about implementing price hikes in the near term. As reported by Anand Rathi, this optimism is supported by the company's volume growth and expansion into new markets. The broker maintains its buy rating based on these positive fundamentals and growth prospects across multiple regions.
